Oncolytics Biotech Secures FDA Type C Meeting for Pelareorep Registrational Pathway

Oncolytics Biotech Inc. has scheduled a Type C meeting with the U.S. Food and Drug Administration (FDA) to evaluate a potential single-arm registrational pathway for its lead therapeutic candidate, pelareorep, specifically for the treatment of anal cancer. The meeting aims to align the company’s development strategy with regulatory expectations for a potentially accelerated path to market.

Pelareorep is an intravenously delivered immunotherapeutic agent designed to promote anti-tumor immunity. By engaging the company with regulators, Oncolytics Biotech seeks to determine if clinical data from a single-arm study could satisfy the requirements for a future Biologics License Application (BLA). The outcome of this discussion is expected to provide critical clarity on the clinical trial design necessary to support the drug's approval process in this indication.

Oncolytics Biotech management noted that the engagement represents a strategic step in advancing their pipeline and addressing the unmet medical needs of patients with anal cancer. The company plans to utilize feedback from the FDA to refine its clinical program and optimize the regulatory roadmap for pelareorep. Further updates regarding the meeting’s conclusions are expected to follow as the company continues its collaboration with the agency.